777: RECURRENCE RATES OF ADVANCED NEOPLASIA AFTER ENDOSCOPIC OR SURGICAL RESECTION IN INFLAMMATORY BOWEL DISEASE PATIENTS: A RETROSPECTIVE COHORT STUDY

Monica E. Derks, Frank Hoentjen(Radboud University Nijmegen), Annemarie C. de Vries(Erasmus MC), Irıs D. Nagtegaal(Radboud University Nijmegen), Lauranne Derikx(Radboud University Nijmegen), Maarten te Groen(Radboud University Nijmegen), Carmen S. Horjus Talabur Horje(Rijnstate Hospital), Gerard Dijkstra(University Medical Center Groningen), Nanne K.H. de Boer, Tessa E H Römkens(Jeroen Bosch Ziekenhuis), Charlotte P. Peters(Amsterdam University Medical Centers)
Gastroenterology
May 1, 2022
10.1016/s0016-5085(22)63926-x
Cited by 0

Related Papers

ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
|Annals of Oncology|2012|1.5k
Interplay of host genetics and gut microbiota underlying the onset and clinical presentation of inflammatory bowel disease
|Gut|2016|800
Endoscopic or surgical step-up approach for infected necrotising pancreatitis: a multicentre randomised trial
|The Lancet|2017|732
Complex host genetics influence the microbiome in inflammatory bowel disease
|Genome Medicine|2014|431
Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial
|The Lancet|2022|301